Shots:
Lundbeck has reported primary P-IIb (PROCEED) trial data assessing bocunebart (Lu AG09222, QM, SC or IV) vs PBO as a preventive treatment in pts with 1-4 prior preventive migraine treatment failures
In the IV group (n=429), bocunebart met its 1EP, reducing monthly migraine days over Wks. 1-12, with a mean reduction of 4.24 vs…
